arrow
D

Doris Quon

orthopedic hemophilia treatment center
H指数:30
被引数:3,385

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Etranacogene dezaparvovec in hemophilia B participants with pre-existing AAV5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial

血友病B参与者中存在AAV5中和抗体的Etranacogene dezaparvovec: hope-b试验的4年亚组结果

2026-01-190
OAAI
Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol

评估血友病关节在急性出血期间关节内组织测量年度变化率的评估:使用关节活动损伤检查(JADE)超声方案

BLOOD
IF23.1
2024-11-050
PRE
Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial

血友病关节健康评分与生活质量之间的关联:基于Xtend-1试验中efanesoctocog alfa III期试验结果

BLOOD
IF23.1
2024-11-050
PRE
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

在3期GENEr8-1试验中,valoctocogenene roxaparvovec基因转移治疗严重血友病A后4年的疗效,安全性和生活质量

2024-11-010
OAAI
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
2024-07-0111
OAAI
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023-02-23146
OA
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
2023-02-23107
OA